Brexit is likely to be delayed and how its Russian roulette with the UK economy
The smart investor knows that the best time to buy is when a stock’s price is low. One of Warren Buffett’s best-known quotes is “Be fearful when others are greedy and greedy when others are afraid”. Or in other words, the time to buy is when everyone is running away. Ray Dalio, the investment genius behind Bridgewater Associates, expresses a similar thought in different words. “Do the opposite of your gut,” he says, advising investors never to trust their instincts. For retail investors, this means stocks that have fallen to very low prices may be just the ticket. They are low priced for a reason, and basically that reason is that investors have jumped ship. The crowd made a choice; but some street analysts see an opportunity. Using the TipRanks database, we identified two battered stocks that received enough praise from Street to achieve a “Strong Buy” consensus rating. Coherus Biosciences (CHRS) We will start with the biotechnology sector, where Coherus Biosciences develops and manufactures biosimilar drugs. These are biologic drugs designed to have a function and target similar to an approved reference drug for which the patents have expired. Cheaper biosimilars are seen as a way to increase patient access to the market for biologics. Coherus currently has one product approved and on the market, and an active pipeline comprising four additional biosimilar drugs. Development programs include treatments in oncology, immunology and ophthalmology. The approved product, Udenyca, is a biosimilar of Neulasta (pegfilgrastim), which stimulates the production of white blood cells and is used to stimulate bone marrow activity in patients undergoing chemotherapy. Udenyca was approved by the FDA and the EU in the fall of 2018. It was marketed as a cheaper alternative to Neulasta, which has tripled in price since its introduction. Coherus’ pipeline projects include biosimilars for Humira (a treatment for Crohn’s disease), Avastin (a treatment for various eye cancers) and Lucentis (a treatment for macular degeneration and diabetic retinopathy). Most of these drugs are in phase 3 clinical trials; CHS-1420, the biosimilar Humira, is currently in the Biologics License Application (BLA) process, a key step before the drug can be marketed. Usually, a pharmaceutical company with a strong product in the market and an active pipeline might expect its shares to rise – but CHRS shares are down, having lost 39% since their peak in January of this year. In its recent first quarter report, Coherus reported a large loss in revenue. EPS came in at less than $ 2.37, a far cry from the 12-cent EPS earnings reported in the fourth quarter. At the top line, the $ 83 million in reported income was the lowest in two years. The losses were attributed by the company to a one-time payment of $ 145 million to Junshi Biosciences under the toripalimab program. Maxim analyst Jason McCarthy acknowledges that CHRS is in a tough spot, but believes the company can chart a course. “The [Q1] miss was largely motivated by pricing pressure and inventory dynamics reducing sales volume for Udenyca. The company expects growth in 2H21, as customers return from OnPro to pre-filled syringes after the pandemic. That said, price pressure will likely play a role in the future, with Amgen reducing the price of the Neulasta brand below the biosimilar, ”noted McCarthy. McCarthy continues of the way forward for CHRS: “Like generics, competition and price erosion, it was a question of when, not if, for biosimilars. Coherus has maintained good pricing discipline, but with increasing competition and Amgen slashing prices, pricing pressure will likely slow Udenyca’s growth. In our view, the pipeline remains attractive in the medium to long term, especially with the move to immuno-oncology… ”The analyst’s outlook supports a buy rating, and his price target of $ 22 implies potential increase over one year of 66%. . (To see McCarthy’s record, click here) Overall, Wall Street still loves Coherus. The stock has been the subject of 7 recent reviews – and they all agree to buy the stock, giving CHRS shares a unanimous Strong Buy consensus rating. The stock is selling for $ 12.95 and its average price target of $ 24.86 implies a 92% increase over the next 12 months. (See CHRS stock market analysis on TipRanks) New Oriental Education (EDU) Let’s change gears, let’s move on to China. The Asian giant has a huge education sector, a product of both the country’s 1.35 billion people and its cultural imperative to provide a solid education for children. The result: a thriving economy of private tutoring and education companies. New Oriental Education lives in this area; the company offers private lessons for primary and secondary students, university preparation courses, assessment test preparation courses and foreign language courses. It also provides technology services, including proprietary educational software products. New Oriental announced its third quarter tax results in April, and the results exceeded expectations. Premium-end revenue rose 29% year-over-year to US $ 1.19 billion, while EPS stood at 10 cents – where analysts said. expected to see 7 cents a share. The gains are attributable to a 42% year-over-year increase in the total number of students enrolled in academic tutoring and test preparation courses. The company also expanded its reach into Chinese schools and continued to open stand-alone learning centers. Despite all of this, and despite today’s 20% jump, shares of New Oriental Education are still down more than 40% since the start of the year following crackdown by government regulators. Modern China has never shied away from bureaucracy, and the current regime has started cracking down on the for-profit education industry. The immediate result has been a lower share price – but perhaps a longer-term opportunity, according to Nomura analyst Jessie Xu. “Considering the overtaking of policies across the industry, we believe EDU should be the most resilient among its peers. We expect the market to appreciate its prominent presence, conservative marketing strategy, strong capital and minimal exposure to preschool education, ”noted Xu. The analyst added, “Although EDU is not immune to potential short-term industry risks. , we believe that all license restrictions [sic] and the advanced management of tuition fees will devastate a number of smaller players and ultimately benefit EDU as an industry leader in the medium term, assuming no significant changes on the demand side occur. Xu believes this is a buyable stock, and his price target of US $ 19 implies 73% growth in the coming year. (To view Xu’s track record, click here) Xu isn’t the only analyst bullish on this stock. His colleagues on the street are giving opinions on EDU 5 Buy, holding a Strong Buy consensus rating. The stock is selling for $ 10.96, and the average price target of $ 18.34 implies that it is 67% higher for the next 12 months. (See EDU Stock Analysis on TipRanks) To find great ideas for battered stocks at attractive valuations, visit TipRanks Best Stocks To Buy, a newly launched tool that brings together all the information about TipRanks stocks. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.